Official patient Web site for FASLODEX® (fulvestrant) Injection 500 mg, a treatment option for postmenopausal women with hormone receptor-positive metastatic breast cancer.
Official patient Web site for FASLODEX® (fulvestrant) Injection 500 mg, a treatment option for postmenopausal women with hormone receptor-positive metastatic breast cancer after treatment with antiestrogen therapy.
Official patient site for FASLODEX® (fulvestrant) Injection 500 mg, a treatment option for postmenopausal women with hormone receptor-positive metastatic breast cancer after treatment with antiestrogen therapy.
This is the research profile of Stephen Ayers, PhD. Visit this page to learn about my research and to learn about the exciting field of gene regulation by members of the nuclear hormone receptor superfamily.
Welcome to the Nuclear Receptor Resource website, dedicated to this important family of ligand-activated transcription factors. On these pages you will find some articles and reviews about various nuclear receptors (NRs). Nuclear Receptor News (NRN) is a
GeneSwitch(TM) Systems, a Inovio, inc. technology. The standard GeneSwitch system for regulated transgene expression exhibits positive control - transgene expression is OFF in the absence of inducing drug, but ON in its presence. Potential applications fo
Journal of Molecular Endocrinology provides a forum for papers devoted to describing the mechanisms underlying the action of hormones and related substances, their regulation in physiological processes and disruption in pathological conditions.
Journal of Endocrinology publishes original molecular, biochemical and physiological studies concerned with the structure and function of the endocrine and endocrine-related systems.